Last quarter Cryoport finally crossed a line it had been promising for more than a year, posting positive adjusted EBITDA from continuing operations ahead of schedule. It then declined to raise its full-year revenue outlook despite a first-half beat. That combination of better margins and a deliberately cautious top line frames the third-quarter report due after the close on November 5. The question now is whether the profitability inflection was a durable shift or a one-quarter high-water mark.
The Street expects a loss of 19 cents a share on revenue of about $48.7 million. Revenue growth of roughly 10% from $44.2 million a year ago is respectable but not spectacular. Revenue would also come in slightly below the $49.0 million delivered last quarter. The per-share loss is forecast to widen modestly from 18 cents a year ago. The whisper number sits a penny below consensus at a 21-cent loss, so the bar on the bottom line is, if anything, slightly lower. On revenue, management's affirmed range of $192 million to $196 million, set against roughly $97 million booked in the first half, implies about $47.5 million to $49.5 million per quarter for the back half. Consensus lands near the middle of that band. That leaves room for a modest beat without assuming anything heroic.
The more revealing figures will sit beneath the headline numbers. Commercial cell and gene therapy services grew 26% last quarter as treatments such as J&J's Carvykti move into community and outpatient settings. Sustaining growth in that range would support the idea that Cryoport's revenue is tilting toward recurring, higher-value commercial work rather than lumpy clinical activity. Biostorage and bioservices have grown at a low-20s percentage clip for four straight quarters, so any slowdown there would stand out. The steady climb in supported clinical trials to 779 matters too, particularly the rise in Phase III programs to 94. Those late-stage trials are the pipeline for future commercial approvals. Last quarter's ORCA Bio approval lifted the commercial therapy count to 22, and further additions would reinforce that pipeline-to-revenue story.
The weak spot was products. MVE freezer sales were flat against a tough comparison after running about 15% growth earlier in the year, even as management held to a high-single-digit full-year outlook. A rebound this quarter, helped by early shipments of the Fusion 811 freezer and the start of local production in China, would validate that outlook. Another flat print would make the full-year products target look stretched. Margins face their own test, because the Paris and Santa Ana supply chain centers are slated to come online in the fourth quarter. Startup costs could begin creeping in now. Keeping adjusted EBITDA positive while absorbing that buildout, and extending the first half's $5 million of operating cash flow, would confirm the profitability turn is structural.
The market has already leaned into that thesis. Shares have gained about 21% since the last report while the S&P 500 was essentially flat. At $18.41, the stock trades far above its 200-day moving average of $13.18 and within 2% of its post-earnings high of $18.73, effectively testing a breakout. Bullish sentiment has also improved from the prior quarter, though it remains well short of euphoric. Together, the price action and sentiment suggest expectations have risen beyond what the modest consensus figures imply.
That sets up a report where meeting estimates may not be enough. The narrative stays intact if Cryoport holds positive adjusted EBITDA, shows products recovering, and either nudges guidance higher or makes clear the macro caution behind last quarter's hold has not hardened into a real headwind. A slip back into negative EBITDA or another soft products quarter would challenge the story, and with the stock near its highs, investors may have little patience for either.